乏血供HCC，靶向药先上多吉美还是特罗凯
有没有乏血供HCC的病友，试过靶向药？交流下经验。
拜谢！！
据说抑制血管新生的多吉美对乏血供（不管HCC，ICC）效果不会好，那么特罗凯？或者其他药？ 有没有人关注多吉美与特罗凯连用，现在的3期试验要到年底才能有结果，坛子里有人试过么？ 与爸爸一起战斗 发表于 2012-9-25 12:16 static/image/common/back.gif
有没有人关注多吉美与特罗凯连用，现在的3期试验要到年底才能有结果，坛子里有人试过么？
已经有个别报导了。
对于HCC，是三期的试验，nct00901901，总生存期并未比单用多吉美提高。毒性如预期。
剂量，每天多吉美400mg*2，特罗凯150mg.
http://www.ukmi.nhs.uk/applicati ... .asp?newDrugID=5211
July 12: Results from the phase 3 SEARCH study: addition of erlotinib to sorafenib did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. sorafenib alone. The safety and tolerability of the treatment combination were generally as expected based upon experience and use of the two products alone and there were no new or unexpected toxicities or changes to the respective product safety profiles observed.
24/07/2012 08:20:52
页:
[1]